Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECVAX-NEO1 plus anti-PD-1/anti-PD-L1 therapy in advanced solid tumors
2024-511212-24-00Phase 2Authorised
- Sponsor
- NEC Corporation
- Start
- Oct 2024
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of NECVAX-NEO1 in Nonhematologic neoplasms (2 arms), sponsored by NEC Corporation. Primary endpoints: Adverse events and serious adverse events and Safety assessments. Planned start Oct 2024; status: authorised.
02
Drugs
NECVAX-NEO1
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-511212-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511212-24-00.